Evidence map›Paper›PMID 29442280›Full record

ArticleInternational journal of clinical pharmacy2018

Patient satisfaction with a chronic kidney disease risk assessment service in community pharmacies.

Pankti A Gheewala, Gregory M Peterson, Syed Tabish R Zaidi, Matthew D Jose, Ronald L Castelino

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pankti A GheewalaDivision of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania, Private Bag 26, Hobart, 7001, Australia. Pankti.Gheewala@utas.edu.au.
Gregory M PetersonDivision of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania, Private Bag 26, Hobart, 7001, Australia.
Syed Tabish R ZaidiDivision of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania, Private Bag 26, Hobart, 7001, Australia.
Matthew D JoseSchool of Medicine, Faculty of Health, University of Tasmania, Private Bag 34, Hobart, TAS, 7000, Australia.
Ronald L CastelinoSydney Nursing School, The University of Sydney, 88 Mallett Street, Camperdown, NSW, 2050, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatient satisfaction is an important determinant of the feasibility and sustainability of community pharmacy screening services. However, few studies have evaluated this, with no such study performed for a chronic kidney disease risk assessment service.

objectiveThe aim was to determine patient satisfaction with a chronic kidney disease risk assessment service performed in community pharmacies.

settingCommunity pharmacies in the state of Tasmania, Australia.

methodAn anonymous nine-item satisfaction survey, with Likert-type scales, was developed following a literature review of existing surveys. Reliability of the nine-item scale was determined using Cronbach's alpha. Patients were asked an additional question on willingness to pay, with choices of amount from $5 to $25. The satisfaction survey was mailed to 389 patients who participated in the chronic kidney disease risk assessment study.

main outcome measurePatient level of satisfaction with and willingness to pay for the chronic kidney disease service.

resultsResponses from 143 participants were included in the final analysis. Cronbach's alpha for the nine-item satisfaction scale was 0.87. The majority of participants agreed that the time required to undergo the risk assessment process was justified (90.2%); overall, they were satisfied with the chronic kidney disease risk assessment service (90.0%) and they felt comfortable with the pharmacist referring their results to their doctor (88.9%). Of 136 participants who answered the question on willingness to pay, 62.9% indicated that they would pay for the chronic kidney disease service. Of these, 29.2, 25.8 and 19.1% were willing to pay $20, $10 and $5, respectively.

conclusionPatient satisfaction with the community pharmacy-based chronic kidney disease risk assessment was high. These findings provide support for the implementation of the service within community pharmacy practice.

Indexed as

Patient SatisfactionProfessional RoleAgedCommunity Pharmacy ServicesFemaleFollow-Up StudiesHumansMaleMiddle AgedPharmacistsRenal Insufficiency, ChronicRisk AssessmentTasmaniaAustraliaChronic kidney diseaseCommunity pharmacyPatient satisfactionQuestionnaireRisk assessment

Identifiers

PMID29442280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.